Anti-polyribosylribitol Phosphate Antibody Concentrations and Avidities in Children Since the Start of Haemophilus Influenzae Type B Immunization of Infants in the United Kingdom

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2008 Sep 12

PMID 18784340

Citations 5

Authors

Dominic F Kelly

E Richard Moxon

Ly-Mee Yu

Andrew J Pollard

Affiliations

Soon will be listed here.

Abstract

The introduction of routine infant immunization with Haemophilus influenzae type b (Hib) conjugate vaccines in the United Kingdom in 1992 led to a significant reduction in invasive disease due to this organism. Subsequently, between 1999 and 2003 there was an increase in the number of immunized children with Hib infection. We investigated whether the rise in cases was related to changes in anti-polyribosylribitol phosphate (PRP) antibody concentration or avidity. Using stored sera, we analyzed temporal changes in antibody levels among 3- to 5-year-old children immunized between 1991 and 2000. Anti-PRP antibody concentrations were higher in 3- to 5-year-olds who received infant immunization in 1991 than those in subsequent years. This difference may be related to changes in either the mode of administration of Hib conjugate vaccines or the rates of Hib nasopharyngeal carriage. This study emphasizes the factors affecting anti-PRP antibody concentration following immunization with conjugate vaccines and the importance of these in long-term protection from invasive disease.

Citing Articles

Impact of Vaccination on Haemophilus influenzae Type b Carriage in Healthy Children Less Than 5 Years of Age in an Urban Population in Nepal.

Shrestha S, Stockdale L, Gautam M, Gurung M, Feng S, Maskey P J Infect Dis. 2021; 224(12 Suppl 2):S267-S274.

PMID: 34469554 PMC: 8409530. DOI: 10.1093/infdis/jiab072.

A high throughput serum bactericidal assay for antibodies to Haemophilus influenzae type b.

Kim H, Kim K, Kim J, Nahm M BMC Infect Dis. 2016; 16:473.

PMID: 27595992 PMC: 5011942. DOI: 10.1186/s12879-016-1808-4.

Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study.

Hammitt L, Crane R, Karani A, Mutuku A, Morpeth S, Burbidge P Lancet Glob Health. 2016; 4(3):e185-94.

PMID: 26853149 PMC: 4763163. DOI: 10.1016/S2214-109X(15)00316-2.

The seroepidemiology of Haemophilus influenzae type b prior to introduction of an immunization programme in Kathmandu, Nepal.

Marshall A, Barker C, Pulickal A, Kibwana E, Gautam S, Clutterbuck E PLoS One. 2014; 9(1):e85055.

PMID: 24465475 PMC: 3898912. DOI: 10.1371/journal.pone.0085055.

Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in Mali.

Hutter J, Pasetti M, Sanogo D, Tapia M, Sow S, Levine M Am J Trop Med Hyg. 2012; 86(6):1026-31.

PMID: 22665612 PMC: 3366516. DOI: 10.4269/ajtmh.2012.11-0807.

References

Anderson P, JOHNSTON Jr R, Smith D . Human serum activities against Hemophilus influenzae, type b. J Clin Invest. 1972; 51(1):31-8. PMC: 332925. DOI: 10.1172/JCI106793. View

Goldblatt D, Vaz A, Miller E . Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis. 1998; 177(4):1112-5. DOI: 10.1086/517407. View

Araujo O, Vespa G, Puccini R, Weckx L, Carvalho E, Farhat C . Associated or combined vaccination of Brazilian infants with a conjugate Haemophilus influenzae type b (Hib) vaccine, a diphtheria-tetanus-whole-cell pertussis vaccine and IPV or OPV elicits protective levels of antibodies against Hib. Vaccine. 2000; 19(2-3):367-75. DOI: 10.1016/s0264-410x(00)00093-1. View

Barbour M, Booy R, Crook D, Griffiths H, Chapel H, Moxon E . Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine. Pediatr Infect Dis J. 1993; 12(6):478-84. DOI: 10.1097/00006454-199306000-00005. View

Trotter C, Ramsay M, Slack M . Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health. 2003; 6(1):55-8. View

Musher D . Pneumococcal vaccine--direct and indirect ("herd") effects. N Engl J Med. 2006; 354(14):1522-4. DOI: 10.1056/NEJMe068038. View

Dagan R, Poolman J, Zepp F . Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev Vaccines. 2008; 7(1):97-115. DOI: 10.1586/14760584.7.1.97. View

Ladhani S, Slack M, Heath P, Ramsay M . Changes in ascertainment of Hib and its influence on the estimation of disease incidence in the United Kingdom. Epidemiol Infect. 2006; 135(5):861-7. PMC: 2870625. DOI: 10.1017/S0950268806007382. View

Ferreccio C, Clemens J, Avendano A, HORWITZ I, Flores C, Avila L . The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six.... Pediatr Infect Dis J. 1991; 10(10):764-71. DOI: 10.1097/00006454-199110000-00009. View

10.

Paradiso P, Hogerman D, Madore D, Keyserling H, King J, Reisinger K . Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Pediatrics. 1993; 92(6):827-32. View

11.

Hoppenbrouwers K, Lagos R, Swennen B, Ethevenaux C, Knops J, Levine M . Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine. 1998; 16(9-10):921-7. DOI: 10.1016/s0264-410x(97)00303-4. View

12.

Scheifele D, Barreto L, Meekison W, Guasparini R, Friesen B . Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid?. CMAJ. 1993; 149(8):1105-12. PMC: 1485444. View

13.

Kelly D, Moxon E, Pollard A . Haemophilus influenzae type b conjugate vaccines. Immunology. 2004; 113(2):163-74. PMC: 1782565. DOI: 10.1111/j.1365-2567.2004.01971.x. View

14.

McVernon J, Howard A, Slack M, Ramsay M . Long-term impact of vaccination on Haemophilus influenzae type b (Hib) carriage in the United Kingdom. Epidemiol Infect. 2004; 132(4):765-7. PMC: 2870159. DOI: 10.1017/s0950268804002122. View

15.

Barbour M, Mayon-White R, Coles C, Crook D, Moxon E . The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis. 1995; 171(1):93-8. DOI: 10.1093/infdis/171.1.93. View

16.

Hviid A, Melbye M . Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine. Vaccine. 2003; 22(3-4):378-82. DOI: 10.1016/j.vaccine.2003.08.001. View

17.

Buttery J, Riddell A, McVernon J, Chantler T, Lane L, Bowen-Morris J . Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA. 2005; 293(14):1751-8. DOI: 10.1001/jama.293.14.1751. View

18.

Gold R, Scheifele D, Barreto L, Wiltsey S, Bjornson G, Meekison W . Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four.... Pediatr Infect Dis J. 1994; 13(5):348-55. DOI: 10.1097/00006454-199405000-00004. View

19.

Trotter C, McVernon J, Andrews N, Burrage M, Ramsay M . Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet. 2003; 361(9368):1523-4. DOI: 10.1016/s0140-6736(03)13172-8. View

20.

Dagan R, Eskola J, Leclerc C, Leroy O . Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun. 1998; 66(5):2093-8. PMC: 108168. DOI: 10.1128/IAI.66.5.2093-2098.1998. View